Notably, we found the existence of a significant positive correlation between an enrichment of GC stemness-related genes included in a stem cell-based signature [33] with FASN overexpression in HER2+ GC patients, thus suggesting that targeting FASN might be clinically relevant to arrest one key survival advantage imparted to CSCs by metabolic plasticity [18]. This evidence concerns the gene ERBB2 and gastric cancer.